Concerning DGAT2, its inhibition with Ervogastat for 14 days appeared to be well tolerated by healthy adults and by MASLD patients, with robust effects of reducing liver fat and serum triglycerides in a dose-dependent manner, although it did not completely repress but rather dampened their production [26]. The gene discussed is DGAT2; the disease is metabolic dysfunction-associated steatotic liver disease.